Ost-müük ALX Oncology Holdings Inc. - ALXO CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.06 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 4.63 |
Avatud* | 4.56 |
Aastane muutus* | -74.44% |
Päeva ulatus* | 4.56 - 4.98 |
52 nädala ulatus | 4.52-19.85 |
Keskmine maht (10 päeva) | 431.68K |
Keskmine maht (3 kuud) | 4.81M |
Turukapitalisatsioon | 189.92M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 40.86M |
Tulu | N/A |
EPS | -3.03 |
Dividendid (% kasumist) | N/A |
Beeta | -100.00K |
Järgmine tuluaruande kuupäev | May 8, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 4.63 | -0.13 | -2.73% | 4.76 | 4.84 | 4.54 |
Mar 23, 2023 | 4.83 | 0.29 | 6.39% | 4.54 | 4.87 | 4.54 |
Mar 22, 2023 | 4.78 | -0.04 | -0.83% | 4.82 | 4.95 | 4.63 |
Mar 21, 2023 | 4.79 | 0.09 | 1.91% | 4.70 | 5.02 | 4.68 |
Mar 20, 2023 | 4.60 | -0.16 | -3.36% | 4.76 | 4.78 | 4.49 |
Mar 17, 2023 | 4.76 | -0.15 | -3.05% | 4.91 | 4.95 | 4.63 |
Mar 16, 2023 | 4.98 | -0.08 | -1.58% | 5.06 | 5.13 | 4.92 |
Mar 15, 2023 | 5.17 | 0.09 | 1.77% | 5.08 | 5.38 | 4.67 |
Mar 14, 2023 | 5.23 | -0.49 | -8.57% | 5.72 | 5.74 | 5.07 |
Mar 13, 2023 | 5.60 | 0.42 | 8.11% | 5.18 | 5.90 | 5.18 |
Mar 10, 2023 | 5.36 | -0.33 | -5.80% | 5.69 | 5.73 | 5.02 |
Mar 9, 2023 | 5.84 | -0.27 | -4.42% | 6.11 | 6.19 | 5.60 |
Mar 8, 2023 | 6.21 | -0.16 | -2.51% | 6.37 | 6.39 | 6.11 |
Mar 7, 2023 | 6.37 | 0.07 | 1.11% | 6.30 | 6.54 | 6.29 |
Mar 6, 2023 | 6.44 | -0.04 | -0.62% | 6.48 | 6.48 | 6.20 |
Mar 3, 2023 | 6.50 | 0.19 | 3.01% | 6.31 | 6.67 | 6.31 |
Mar 2, 2023 | 6.45 | 0.11 | 1.74% | 6.34 | 6.47 | 6.23 |
Mar 1, 2023 | 6.48 | 0.04 | 0.62% | 6.44 | 6.60 | 6.43 |
Feb 28, 2023 | 6.59 | 0.16 | 2.49% | 6.43 | 6.66 | 6.43 |
Feb 27, 2023 | 6.63 | 0.15 | 2.31% | 6.48 | 6.74 | 6.48 |
ALX Oncology Holdings Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 1.182 | 4.796 | 2.067 |
Tulu | 0 | 0 | 1.182 | 4.796 | 2.067 |
Kulud, Kokku | 0 | 1.075 | 4.36 | 1.88 | |
Brutokasum | 0 | 0.107 | 0.436 | 0.187 | |
Kogu tegevuskulu | 127.436 | 83.555 | 45.466 | 23.979 | 15.751 |
Müük/Üldine/admin kulud, kokku | 29.036 | 23.385 | 14.809 | 3.313 | 2.601 |
Uuringud ja arendus | 98.4 | 60.17 | 28.961 | 16.306 | 11.27 |
Tulud majandustegevusest | -127.436 | -83.555 | -44.284 | -19.183 | -13.684 |
Intressitulud (kulu), muud tulud, neto | 4.278 | -0.013 | -0.811 | -0.021 | 0 |
Muud, neto | -0.26 | 0.084 | -0.404 | -0.005 | -0.002 |
Netotulu enne makse | -123.418 | -83.484 | -45.499 | -19.209 | -13.686 |
Netotulu pärast makse | -123.482 | -83.463 | -45.74 | -19.243 | -13.731 |
Netotulu enne erikulusid | -123.482 | -83.463 | -45.74 | -19.243 | -13.731 |
Netotulu | -123.482 | -83.463 | -45.74 | -19.243 | -13.731 |
Total Adjustments to Net Income | 0 | 0 | -5.202 | -4.028 | -3.671 |
Arvestatav tulu, v a erikulud | -123.482 | -83.463 | -50.942 | -23.271 | -17.402 |
Arvestatav tulu, koos erikuludega | -123.482 | -83.463 | -50.942 | -23.271 | -17.402 |
Jaotamisele kuuluv netotulu | -123.482 | -83.463 | -50.942 | -23.271 | -17.402 |
Keskmine jaotamisele kuuluv aktsia kohta | 40.6996 | 40.308 | 18.4853 | 34.7116 | 34.7116 |
Jaotatav EPS, v a erakorralised kulud | -3.03398 | -2.07063 | -2.7558 | -0.67041 | -0.50133 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Jaotamisele kuuluv normaal-EPS | -3.03398 | -2.07063 | -2.73397 | -0.67041 | -0.50133 |
Ootamatud kulutused (tulu) | 0 | 0 | 0.621 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Tulu | 0 | ||||
Kogu tegevuskulu | 32.219 | 36.681 | 33.789 | 24.747 | 28.472 |
Müük/Üldine/admin kulud, kokku | 7.022 | 7.299 | 7.041 | 7.674 | 7.578 |
Uuringud ja arendus | 25.197 | 29.382 | 26.748 | 17.073 | 20.894 |
Tulud majandustegevusest | -32.219 | -36.681 | -33.789 | -24.747 | -28.472 |
Intressitulud (kulu), muud tulud, neto | 1.807 | 1.37 | 0.876 | 0.225 | -0.003 |
Muud, neto | -0.233 | -0.009 | -0.007 | -0.011 | 0.016 |
Netotulu enne makse | -30.645 | -35.32 | -32.92 | -24.533 | -28.459 |
Netotulu pärast makse | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Netotulu enne erikulusid | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Netotulu | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Total Adjustments to Net Income | 0 | ||||
Arvestatav tulu, v a erikulud | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Arvestatav tulu, koos erikuludega | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Jaotamisele kuuluv netotulu | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Keskmine jaotamisele kuuluv aktsia kohta | 40.7459 | 40.747 | 40.6878 | 40.6163 | 40.5297 |
Jaotatav EPS, v a erakorralised kulud | -0.75367 | -0.86681 | -0.80909 | -0.60402 | -0.70166 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Jaotamisele kuuluv normaal-EPS | -0.75367 | -0.86681 | -0.80909 | -0.60402 | -0.70166 |
Kulud, Kokku | |||||
Brutokasum | |||||
Ootamatud kulutused (tulu) | 0 | 0 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Käibevarad kokku | 367.019 | 435.992 | 9.809 | 10.208 |
Raha ja lühiajalised investeeringud | 363.667 | 434.219 | 9.017 | 8.262 |
Cash | 434.219 | 9.017 | 8.262 | |
Laekumata arved, neto | 0 | 0.536 | 0.932 | |
Accounts Receivable - Trade, Net | 0 | 0.536 | 0.932 | |
Prepaid Expenses | 3.352 | 1.773 | 0.256 | 1.014 |
Total Assets | 380.183 | 436.054 | 10.676 | 11.164 |
Property/Plant/Equipment, Total - Net | 3.397 | 0.052 | 0.86 | 0.956 |
Property/Plant/Equipment, Total - Gross | 3.46 | 0.077 | 2.309 | 1.976 |
Accumulated Depreciation, Total | -0.063 | -0.025 | -1.449 | -1.02 |
Other Long Term Assets, Total | 9.767 | 0.01 | 0.007 | 0 |
Total Current Liabilities | 15.295 | 6.204 | 4.984 | 1.873 |
Accounts Payable | 3.764 | 0.004 | 3.748 | 0.697 |
Accrued Expenses | 11.102 | 6.049 | 1.046 | 0.905 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.151 | 0.19 | 0.271 | |
Total Liabilities | 17.134 | 6.209 | 10.952 | 2.009 |
Total Long Term Debt | 0.28 | 0 | 5.421 | 0 |
Long Term Debt | 5.421 | 0 | ||
Other Liabilities, Total | 1.559 | 0.005 | 0.547 | 0.136 |
Total Equity | 363.049 | 429.845 | -0.276 | 9.155 |
Preferred Stock - Non Redeemable, Net | 70.363 | 60.933 | ||
Common Stock | 0.041 | 0.04 | 0.021 | 0.021 |
Additional Paid-In Capital | 564.993 | 548.327 | 2.122 | 1.74 |
Retained Earnings (Accumulated Deficit) | -201.985 | -118.522 | -72.782 | -53.539 |
Total Liabilities & Shareholders’ Equity | 380.183 | 436.054 | 10.676 | 11.164 |
Total Common Shares Outstanding | 40.5871 | 39.8445 | 34.7116 | 34.7116 |
Redeemable Preferred Stock | 0 | |||
Raha ja ekvivalendid | 363.667 | |||
Current Port. of LT Debt/Capital Leases | 0.429 | |||
Capital Lease Obligations | 0.28 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 321.525 | 367.019 | 388.963 | 412.277 | 432.327 |
Raha ja lühiajalised investeeringud | 316.596 | 363.667 | 385.149 | 409.964 | 429.855 |
Raha ja ekvivalendid | 159.086 | 363.667 | 385.149 | 409.964 | 429.855 |
Prepaid Expenses | 4.929 | 3.352 | 3.814 | 2.313 | 2.472 |
Total Assets | 363.676 | 380.183 | 399.728 | 421.289 | 432.91 |
Property/Plant/Equipment, Total - Net | 6.967 | 3.397 | 3.362 | 0.167 | 0.047 |
Property/Plant/Equipment, Total - Gross | 7.088 | 3.46 | 3.401 | 0.2 | 0.077 |
Accumulated Depreciation, Total | -0.121 | -0.063 | -0.039 | -0.033 | -0.03 |
Other Long Term Assets, Total | 10.075 | 9.767 | 7.403 | 8.845 | 0.536 |
Total Current Liabilities | 15.308 | 15.295 | 12.488 | 13.979 | 14.129 |
Accounts Payable | 5.133 | 3.764 | 3.683 | 5.806 | 7.35 |
Accrued Expenses | 9.746 | 11.102 | 8.376 | 7.744 | 2.735 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.429 | 0.429 | 0.429 | 0.429 | 0.095 |
Other Current Liabilities, Total | 3.949 | ||||
Total Liabilities | 20.08 | 17.134 | 14.556 | 16.275 | 14.426 |
Total Long Term Debt | 0.175 | 0.28 | 0.385 | 0.489 | 0.131 |
Capital Lease Obligations | 0.175 | 0.28 | 0.385 | 0.489 | 0.131 |
Other Liabilities, Total | 4.597 | 1.559 | 1.683 | 1.807 | 0.166 |
Total Equity | 343.596 | 363.049 | 385.172 | 405.014 | 418.484 |
Redeemable Preferred Stock | 0 | ||||
Common Stock | 0.041 | 0.041 | 0.04 | 0.04 | 0.04 |
Additional Paid-In Capital | 570.679 | 564.993 | 558.679 | 553.955 | 551.151 |
Retained Earnings (Accumulated Deficit) | -226.518 | -201.985 | -173.547 | -148.981 | -132.707 |
Total Liabilities & Shareholders’ Equity | 363.676 | 380.183 | 399.728 | 421.289 | 432.91 |
Total Common Shares Outstanding | 40.6566 | 40.5871 | 40.4863 | 40.3253 | 40.2086 |
Lühiajalised investeeringud | 157.51 | ||||
Long Term Investments | 25.109 | ||||
Other Equity, Total | -0.606 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Netotulu/algväärtus | -83.463 | -45.74 | -19.243 | -13.731 |
Raha majandustegevusest | -68.101 | -38.289 | -14.249 | -13.19 |
Raha majandustegevusest | 0.051 | 0.202 | 0.429 | 0.431 |
Mittelikviidsed varad | 19.338 | 7.002 | 0.308 | 0.269 |
Muutused tööjõus | -4.027 | 0.247 | 4.257 | -0.159 |
Tulu investeeringutelt | -4.923 | 0.61 | -0.353 | -0.653 |
Kapitalikulutused | -4.923 | -0.031 | -0.353 | -0.653 |
Rahavood investeeringutelt | 2.472 | 462.881 | 15.357 | 0.001 |
Aktsiate emiteerimine (tagasiost), neto | 2.753 | 473.235 | 9.44 | 0.001 |
Laenu väljastamine (kustutamine), neto | -0.281 | 0 | 5.917 | 0 |
Rahaline kogumuutus | -70.552 | 425.202 | 0.755 | -13.842 |
Cash Taxes Paid | 0.274 | 0.047 | ||
Makstud intressid | 0.011 | 0.427 | ||
Muud rahavood investeeringutelt, kokku | 0.641 | |||
Rahavoogudesse investeerimine | -10.354 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -24.533 | -83.463 | -55.025 | -30.459 | -14.185 |
Cash From Operating Activities | -20.674 | -68.101 | -50.613 | -25.757 | -5.135 |
Cash From Operating Activities | 0.058 | 0.051 | 0.017 | 0.011 | 0.005 |
Non-Cash Items | 5.926 | 19.338 | 8.688 | 4.241 | 1.858 |
Cash Interest Paid | 0 | 0.011 | 0.007 | 0.003 | 0 |
Changes in Working Capital | -2.125 | -4.027 | -4.293 | 0.45 | 7.187 |
Cash From Investing Activities | -183.921 | -4.923 | -0.405 | -0.007 | -0.007 |
Capital Expenditures | -0.589 | -4.923 | -0.405 | -0.007 | -0.007 |
Cash From Financing Activities | 0.08 | 2.472 | 1.948 | 1.509 | 0.778 |
Issuance (Retirement) of Stock, Net | 0.185 | 2.753 | 2.125 | 1.582 | 0.778 |
Net Change in Cash | -204.515 | -70.552 | -49.07 | -24.255 | -4.364 |
Cash Taxes Paid | 0 | 0.274 | 0.274 | 0.274 | |
Financing Cash Flow Items | 0 | 0 | |||
Issuance (Retirement) of Debt, Net | -0.105 | -0.281 | -0.177 | -0.073 | |
Other Investing Cash Flow Items, Total | -183.332 | 0 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
VenBio Partners LLC | Private Equity | 23.8003 | 9699925 | 0 | 2022-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 14.9987 | 6112789 | 1482504 | 2022-12-31 | LOW |
Lightstone Ventures, L.P. | Investment Advisor | 11.1076 | 4526963 | -194027 | 2022-03-31 | LOW |
Vivo Capital, LLC | Venture Capital | 10.3546 | 4220048 | 0 | 2022-12-31 | MED |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 7.0445 | 2871000 | 0 | 2022-12-31 | LOW |
Logos Global Management LLC | Investment Advisor | 5.7651 | 2349600 | -621752 | 2022-12-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.7051 | 1510050 | 40991 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.4941 | 1424043 | 14289 | 2022-12-31 | LOW |
Eventide Asset Management, LLC | Investment Advisor | 2.2132 | 902000 | 0 | 2022-12-31 | MED |
Cormorant Asset Management, LP | Hedge Fund | 1.5018 | 612079 | -100000 | 2022-12-31 | MED |
Redmile Group, LLC | Investment Advisor/Hedge Fund | 1.4905 | 607470 | -144627 | 2022-12-31 | LOW |
Pons (Jaume) | Individual Investor | 1.3244 | 539746 | -3232 | 2022-12-29 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.2268 | 500000 | 0 | 2022-12-31 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 1.171 | 477236 | 90049 | 2022-12-31 | MED |
Federated Hermes MDTA LLC | Investment Advisor/Hedge Fund | 1.1386 | 464029 | -685 | 2022-12-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0117 | 412309 | 18988 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.9656 | 393550 | 8987 | 2022-12-31 | LOW |
DWS Investments UK Limited | Investment Advisor | 0.84 | 342355 | 142 | 2022-12-31 | MED |
Pier Capital, LLC | Investment Advisor | 0.667 | 271848 | -769 | 2022-12-31 | MED |
Randolph (Sophia) | Individual Investor | 0.6631 | 270253 | 44857 | 2022-12-29 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
ALX Oncology Holdings Inc. Company profile
Ettevõttest ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc. on kliinilises staadiumis immunonkoloogia ettevõte. Ettevõte keskendub sellele, et võimaldada patsientidel võidelda vähiga, arendades ravimeid, mis blokeerivad kontrollpunkti klastri 47 (CD47) kontrollrada ja sillutavad kaasasündinud ja adaptiivset immuunsüsteemi. Ettevõte töötab välja kontrollpunkti inhibiitorit, mis on loodud nii, et see omab afiinsust CD47 suhtes ja väldib hematoloogilistest toksilisustest tingitud piiranguid, mis on omane teistele CD47 blokeerivatele lähenemisviisidele. Ettevõtte juhtiv tootekandidaat ALX148 on CD47 blokeeriv ravim. ALX148 on fusioonvalk, mis ühendab CD47 sidumisdomeeni selle inaktiveeritud kristalliseeruva fragmendi (Fc) domeeniga. ALX148 CD47 sidumisdomeen on signaali regulatiivse valgu alfa (SIRPa), mis on müeloidrakkudel leiduv CD47 looduslik retseptor, afiinsuse suurendamisega ekstratsellulaarne domeen. Tema programmid on suunatud CD47 sihtmärgiks erinevates onkoloogilistes näidustustes.
Industry: | Bio Therapeutic Drugs |
323 Allerton Avenue
94080
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com